BioCentury
ARTICLE | Clinical News

CVTX starts CVT-3146 Phase II

August 21, 2001 7:00 AM UTC

CV Therapeutics (CVTX) began Phase II testing of its CVT-3146 selective A2A adenosine receptor agonist for use in cardiac perfusion imaging. The study will measure the tolerability of the product and ...